Number: CTEP 8762 Principal Investigator: Ma, Cynthia
Title: A Phase 1 Trial of MK-2206 in Combination with Anastrozole, Fulvestrant, or Anastrozole plus Fulvestrant in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer
Phase: I Disease Site: Breast, Female
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

The purpose of this research study is to find out what effects, good and/or bad, the drug MK-2206 has on patients and their metastatic breast cancer when given in combination with hormonal therapy (anastrozole or letrozole), which blocks or limits the production of estrogen, which estrogen receptor-positive breast cancer cells need in order to grow. We want to find out the safety and the tolerable dose of MK-2206 when it is combined with either anastrozole or letrozole.
MK-2206 is considered investigational, which means that it has not been approved by the U.S. Food and Drug Administration (FDA). MK-2206 inhibits the activity of a protein that is important for cancer cell growth, which means that it can help prevent cancer cells from growing. Studies in laboratories suggest that combining MK-2206 with hormonal therapy which is already used in the treatment of breast cancer, such as anastrozole or letrozole, may kill cancer cells in the particular kind of breast cancer that you have.
More Information:
Internal Protocol Documents (requires Siteman administrative database password)